The following is a listing of myeloma treatments associated with this tag.
View all treatments in development for myeloma patients around the US.
The following is a listing of treatments in development for patients with multiple myeloma who have received one to two prior lines of therapy.
The following is a listing of treatments in development for patients with multiple myeloma who have received three or more prior lines of therapy.
The following is a listing of myeloma clinical trials associated with this tag.
View all active clinical trials around the US.
Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma
VENETOCLAX AND TOCILIZUMAB FOR T(11;14)SparkCures Verified Accurate, up-to-date information. Learn more
A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)
THE BEAT AML TRIALA Phase 1 Study of Adding Venetoclax to a Reduced Intensity Conditioning Regimen and to Maintenance in Comb...
VENETOCLAX IN PRE- AND POST-TRANSPLANT THERAPYA Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination With Standard Intensive AML Induction/C...
VENETOCLAX W/ COMBINATION CHEMOTHERAPYA Phase I Study Investigating the Safety & Efficacy of Danvatirsen as Monotherapy Followed by Combination W...
DANVATIRSEN PLUS VENETOCLAXA Phase I/II Study of ASTX727, Venetoclax, and Gilteritinib for Patients With Acute Myeloid Leukemia or Hig...
ASTX727, VENETOCLAX, AND GILTERITINIBA Phase I/II Study of Azacitidine, Venetoclax, and Gilteritinib for Patients With Acute Myeloid Leukemia or...
AZACITIDINE, VENETOCLAX, AND GILTERITINIBA Phase I/II Study of Quizartinib in Combination With Decitabine and Venetoclax for the Treatment of Patien...
QUIZARTINIB WITH DECITABINE AND VENETOCLAXA Phase I/II Study of Venetoclax in Combination With Azacitidine in Relapsed/Refractory High-Risk Myelodysp...
VENETOCLAX PLUS AZACITIDINEA Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Aza...
CLADRIBINE, CYTARABINE AND VENETOCLAX FOR HR-MDSMetabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
LOW DOSE WEEKLY DECITABINE/VENETOCLAXPhase 1b Study of Pembrolizumab, Decitabine +/- Venetoclax Combination Therapy in Patients With Relapsed or...
PEMBROLIZUMAB, DECITABINE +/- VENETOCLAXPhase 1B Study of Venetoclax in Combination With Standard Intensive Chemotherapy With Daunorubicin Plus Cyt...
VENETOCLAX PLUS INTENSIVE CHEMOTHERAPYPhase I Clinical Trial of Bcl2 Inhibitor Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven...
VENETOCLAX PLUS LENALIDOMIDEPhase I/II of Venetoclax in Combination With Azacitidine in Treatment Naïve and Relapse Refractory High Ris...
VENETOCLAX PLUS AZACITIDINEPhase II Study of Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With AML, HR MDS, or Myeloi...
CHEMOTHERAPY PLUS VENETOCLAXPhase II Study of Clinical Efficacy of Venetoclax in Combination With Azacitidine in Patients With Therapy ...
VENETOCLAX AND AZACITIDINE FOR THERAPY-RELATED MDSVenetoclax in Combination With ASTX727, an All-ORal Therapy for Chronic Myelomonocytic Leukemia and Other M...
VENETOCLAX IN COMBINATION WITH ASTX727Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
VENETOCLAX AS PART OF PRE-TRANSPLANT CHEMOTHERAPYThe following is a listing of clinical trials for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.
Phase I Clinical Trial of Bcl2 Inhibitor Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven...
VENETOCLAX PLUS LENALIDOMIDEThe following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.
SparkCures Verified Accurate, up-to-date information. Learn more
Phase I Clinical Trial of Bcl2 Inhibitor Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven...
VENETOCLAX PLUS LENALIDOMIDEThe following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.
Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma
VENETOCLAX AND TOCILIZUMAB FOR T(11;14)SparkCures Verified Accurate, up-to-date information. Learn more